Verve shares first base edit­ing re­sults in hu­mans, sug­gest­ing ther­a­py can low­er cho­les­terol in pa­tients with ge­net­ic con­di­tion

PHILADEL­PHIA — Verve Ther­a­peu­tics’ next-gen­er­a­tion gene edit­ing treat­ment low­ered cho­les­terol lev­els in a hand­ful of pa­tients with het­erozy­gous fa­mil­ial hy­per­c­ho­les­terolemia, mark­ing the first time that base …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER